XGEVA®

(Denosumab)

Documentation

Patented
Approved 2010
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: CD254(RANKL)
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA